MedCity News May 8, 2024
Transcarent recently announced that it raised $126 million in Series D funding led by General Catalyst and 7wireVentures. When asked what his exit strategy is, CEO Glen Tullman said he does not want to sell Transcarent, but sees an initial public offering as an option.
After care navigation company Transcarent announced last week that it raised $126 million in Series D funding, CEO Glen Tullman told MedCity News that he has “no interest” in selling the company. However, an initial public offering (IPO) — when a privately owned company sells shares of stock to the public — is a possibility, he said.
“I have run four public companies and have gone through three IPOs, so it’s a question I often...
Today's Sponsors
Today's Sponsor